The COVID vaccine brought a renewed public debate around vaccines. A new film airing on PBS explores the politicization of ...

The virus found in wastewater is no longer infectious, but officials said it shows that people in the area may be carrying ...

Wastewater samples collected in Greenville spurs health officials to urge awareness and caution, these samples contained a ...

There are two vaccines approved by the FDA -- RotaTeq and Rotarix -- that protect against rotavirus, the most common cause of ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...

voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease ...

voted in favour of recommending the use of RSV vaccines including GSK’s Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50-59 who are at increased risk for severe RSV disease.

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.